Tildrakizumab Enhances Regulatory T Cells, Inhibits PsA Progression in Elderly Patients
At the 7-month mark, multivariate analysis revealed patients with psoriasis aged ≥65 years reported a significantly better response to tildrakizumab.
Source: hcplive.com